New research compares flotufolastat F 18 and piflufolastat F 18 detection rates in recurrent prostate cancer and evaluates fluciclovine F 18 PET/CT for brain metastases. Blue Earth Diagnostics, part of the Bracco Group, will present new research on precision molecular imaging at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting , Sept 26-30, in Boston. The data span recurrent prostate cancer and brain metastases, addressing clinical scenarios in which conventional measures or imaging alone may leave uncertainty about the location or extent of disease.
The presentations focus on two distinct clinical challenges. In recurrent prostate cancer, rising prostate-specific antigen (PSA) levels may signal disease return without indicating its location. In patients with brain metastases, post-operative changes can make it difficult to distinguish treatment-related effects from tumor necrosis or pseudoprogression.
Head-to-Head PSMA PET Comparison The first presentation showcases an analysis from the first intra-patient, head-to-head comparator study of flotufolastat F 18 (Posluma) and piflufolastat F 18, examining detection rates in men with biochemical recurrence follow...